T. Rowe Price Associates’s Enzo Biochem, Inc. ENZ Stock Holding History

T. Rowe Price Associates’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-44,800	Closed	-$17K	–	3175
2025 Q1	$17K	Hold	44,800	–	–	﹤0.01%	3012
2024 Q4	$32K	Hold	44,800	–	–	﹤0.01%	2973
2024 Q3	$51K	Hold	44,800	–	–	﹤0.01%	2927
2024 Q2	$49K	Hold	44,800	–	–	﹤0.01%	2859
2024 Q1	$57K	Hold	44,800	–	–	﹤0.01%	2860
2023 Q4	$63K	Hold	44,800	–	–	﹤0.01%	2773
2023 Q3	$63K	Hold	44,800	–	–	﹤0.01%	2747
2023 Q2	$83K	Hold	44,800	–	–	﹤0.01%	2726
2023 Q1	$109K	Hold	44,800	–	–	﹤0.01%	2668
2022 Q4	$64K	Hold	44,800	–	–	﹤0.01%	2783
2022 Q3	$100K	Hold	44,800	–	–	﹤0.01%	2727
2022 Q2	$93K	Hold	44,800	–	–	﹤0.01%	2768
2022 Q1	$130K	Hold	44,800	–	–	﹤0.01%	2802
2021 Q4	$144K	Hold	44,800	–	–	﹤0.01%	2818
2021 Q3	$159K	Hold	44,800	–	–	﹤0.01%	2768
2021 Q2	$142K	Sell	44,800 -11,563	-21%	-$36.4K	﹤0.01%	2789
2021 Q1	$194K	Sell	56,363 -37,918	-40%	-$118K	﹤0.01%	2698
2020 Q4	$238K	Hold	94,281	–	–	﹤0.01%	2507
2020 Q3	$199K	Buy	94,281 +31,000	+49%	+$73.7K	﹤0.01%	2421
2020 Q2	$142K	Buy	63,281 +47,901	+311%	+$123K	﹤0.01%	2399
2020 Q1	$39K	Hold	15,380	–	–	﹤0.01%	2467
2019 Q4	$40K	Buy	15,380 +1,749	+13%	+$5.22K	﹤0.01%	2503
2019 Q3	$49K	Buy	13,631 +188	+1%	+$665	﹤0.01%	2489
2019 Q2	$45K	Buy	13,443 +100	+0.7%	+$352	﹤0.01%	2519
2019 Q1	$36K	Buy	13,343 +100	+0.8%	+$327	﹤0.01%	2512
2018 Q4	$37K	Sell	13,243 -100	-0.7%	-$328	﹤0.01%	2535
2018 Q3	$55K	Hold	13,343	–	–	﹤0.01%	2564
2018 Q2	$69K	Buy	13,343 +54	+0.4%	+$329	﹤0.01%	2551
2018 Q1	$73K	Buy	13,289 +80	+0.6%	+$564	﹤0.01%	2520
2017 Q4	$108K	Hold	13,209	–	–	﹤0.01%	2499
2017 Q3	$138K	Hold	13,209	–	–	﹤0.01%	2465
2017 Q2	$146K	Hold	13,209	–	–	﹤0.01%	2437
2017 Q1	$111K	Sell	13,209 -46	-0.3%	-$324	﹤0.01%	2479
2016 Q4	$92K	Hold	13,255	–	–	﹤0.01%	2476
2016 Q3	$67K	Buy	13,255 +155	+1%	+$926	﹤0.01%	2485
2016 Q2	$78K	Hold	13,100	–	–	﹤0.01%	2453
2016 Q1	$60K	Hold	13,100	–	–	﹤0.01%	2463
2015 Q4	$59K	Hold	13,100	–	–	﹤0.01%	2467
2015 Q3	$42K	Hold	13,100	–	–	﹤0.01%	2478
2015 Q2	$40K	Hold	13,100	–	–	﹤0.01%	2508
2015 Q1	$39K	Hold	13,100	–	–	﹤0.01%	2518
2014 Q4	$58K	Hold	13,100	–	–	﹤0.01%	2511
2014 Q3	$67K	Hold	13,100	–	–	﹤0.01%	2503
2014 Q2	$69K	Hold	13,100	–	–	﹤0.01%	2491
2014 Q1	$54K	Hold	13,100	–	–	﹤0.01%	2476
2013 Q4	$38K	Hold	13,100	–	–	﹤0.01%	2470
2013 Q3	$33K	Hold	13,100	–	–	﹤0.01%	2447
2013 Q2	$27K	Buy	+13,100	New	+$28.9K	﹤0.01%	2420

Other funds holding ENZ

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

KCM

Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

T. Rowe Price Associates's ENZ Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 44,800 shares — an estimated $17K sold.

T. Rowe Price Associates first reported a position in ENZ in Q2 2013 and held it in 48 quarters. The position peaked at $238K in Q4 2020. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

T. Rowe Price Associates reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 44,800 Enzo Biochem, Inc. shares in Q2 2025, an estimated $17K.
T. Rowe Price Associates first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 48 quarters.
T. Rowe Price Associates's Enzo Biochem, Inc. position peaked at $238K in Q4 2020.
6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.